Opinion|Videos|May 5, 2025
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
Advertisement
Video content above is prompted by the following:
- Currently, how prevalent is Lp(a) testing in the US, both in the overall population and among those with established ASCVD?
- How common is Lp(a) testing within the health plans that you work with?
- How can payers, population health decision makers working at health systems, and provider groups infuse Lp(a) testing into their larger population health management infrastructure?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
2
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
3
The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5
